Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 4/20 | 0.43 |
| ▸ | BCHE | P06276 | 10/20 | 0.41 |
| ▸ | ACHE | P22303 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7165428 | 0.92 | LMNA (0.57) | LMNAMEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7983425 | 0.83 | MAPT (0.46) | LMNABCHEACHEMEN1KMT2A | |
| SCHEMBL6912027 | 0.80 | KIF11 (0.42) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6912324 | 0.80 | KIF11 (0.42) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6905934 | 0.80 | KIF11 (0.42) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6906578 | 0.79 | LMNA (0.48) | LMNAXDHBCHEACHEMEN1 | |
| SCHEMBL7072940 | 0.73 | KIF11 (0.35) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7980653 | 0.73 | MAPT (0.40) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7977148 | 0.73 | MAPT (0.40) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7980852 | 0.73 | MAPT (0.40) | LMNAMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242485-A1 | Compositions and methods for the amelioration of leptin resistance | KADOWAKI TAKASHI (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-0882707-B1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | ASAHI CHEMICAL IND (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
| US-20030073644-A1 | Combinations comprising a beta-agonist and a further antidiabetic agent | SMITHKLINE BEECHAM P.L.C. | 2003-04-17 | — | — | US | disclosed |
| US-6545053-B1 | Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-04-08 | — | — | US | disclosed |
| EP-1128845-A1 | COMBINATIONS COMPRISING A BETA-AGONIST AND A FURTHER ANTDIABETIC AGENT | SMITHKLINE BEECHAM PLC (GB) | 2001-09-05 | — | — | EP | disclosed |
| US-6187809-B1 | BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| WO-2000027434-A1 | COMBINATIONS COMPRISING A BETA-AGONIST AND A FURTHER ANTIDIABETIC AGENT | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-18 | — | — | WO | disclosed |
| US-6037362-A | CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ADRB3, MC2R, NR3C1 | LMNA 3391/4885XDH 418/4885BCHE 698/4885 |
| US-20030073644-A1 | Combinations comprising a beta-agonist and a further antidiabetic agent | ADRB1, ADRB2, ADRB3 | LMNA 2135/4885XDH 1458/4885BCHE 406/4885 |
| US-20040242485-A1 | Compositions and methods for the amelioration of leptin resistance | ADIPOR1, FABP4, ADIPOR2 | LMNA 435/4885XDH 1791/4885BCHE 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.